Contineum Therapeutics (CTNM) Competitors

Contineum Therapeutics logo
$9.55 -0.12 (-1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$9.55 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CTNM vs. RAPP, GPCR, LBRX, OCUL, and PCRX

Should you buy Contineum Therapeutics stock or one of its competitors? Contineum Therapeutics's main competitors and comparable companies include Rapport Therapeutics (RAPP), Structure Therapeutics (GPCR), LB Pharmaceuticals (LBRX), Ocular Therapeutix (OCUL), and Pacira BioSciences (PCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Contineum Therapeutics compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Rapport Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Contineum Therapeutics' return on equity of -25.48% beat Rapport Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -34.00% -31.89%
Contineum Therapeutics N/A -25.48%-24.28%

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$111.48M-$3.17N/A
Contineum TherapeuticsN/AN/A-$59.98M-$1.77N/A

Rapport Therapeutics currently has a consensus price target of $64.50, suggesting a potential upside of 171.46%. Contineum Therapeutics has a consensus price target of $21.40, suggesting a potential upside of 124.08%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Contineum Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 2 mentions for Contineum Therapeutics and 1 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 1.56 beat Contineum Therapeutics' score of 0.96 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapport Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Rapport Therapeutics and Contineum Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Contineum Therapeutics compare to Structure Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Contineum Therapeutics' return on equity of -25.48% beat Structure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -25.48% -24.28%
Structure Therapeutics N/A -29.18%-27.62%

Structure Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum TherapeuticsN/AN/A-$59.98M-$1.77N/A
Structure TherapeuticsN/AN/A-$141.20M-$1.29N/A

Contineum Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.12, meaning that its share price is 212% less volatile than the broader market.

In the previous week, Structure Therapeutics had 15 more articles in the media than Contineum Therapeutics. MarketBeat recorded 17 mentions for Structure Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.96 beat Structure Therapeutics' score of 0.56 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Structure Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

91.8% of Structure Therapeutics shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Contineum Therapeutics presently has a consensus target price of $21.40, suggesting a potential upside of 124.08%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 510.40%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Structure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

Summary

Contineum Therapeutics and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Contineum Therapeutics' return on equity of -25.48% beat LB Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
LB PharmaceuticalsN/A -39.49% -37.12%
Contineum Therapeutics N/A -25.48%-24.28%

LB Pharmaceuticals currently has a consensus price target of $57.40, suggesting a potential upside of 42.43%. Contineum Therapeutics has a consensus price target of $21.40, suggesting a potential upside of 124.08%. Given Contineum Therapeutics' higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LB Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

LB Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, LB Pharmaceuticals had 12 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.96 beat LB Pharmaceuticals' score of 0.66 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LB Pharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LB PharmaceuticalsN/AN/A-$25.20M-$4.62N/A
Contineum TherapeuticsN/AN/A-$59.98M-$1.77N/A

Summary

Contineum Therapeutics beats LB Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Contineum Therapeutics compare to Ocular Therapeutix?

Contineum Therapeutics (NASDAQ:CTNM) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Ocular Therapeutix had 19 more articles in the media than Contineum Therapeutics. MarketBeat recorded 21 mentions for Ocular Therapeutix and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.96 beat Ocular Therapeutix's score of 0.17 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocular Therapeutix
3 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Contineum Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Contineum Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum TherapeuticsN/AN/A-$59.98M-$1.77N/A
Ocular Therapeutix$50.38M26.29-$265.94M-$1.46N/A

59.2% of Ocular Therapeutix shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Contineum Therapeutics presently has a consensus target price of $21.40, suggesting a potential upside of 124.08%. Ocular Therapeutix has a consensus target price of $23.83, suggesting a potential upside of 295.90%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Contineum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -648.64%. Contineum Therapeutics' return on equity of -25.48% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -25.48% -24.28%
Ocular Therapeutix -648.64%-59.95%-46.75%

Summary

Ocular Therapeutix beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Pacira BioSciences currently has a consensus price target of $33.33, suggesting a potential downside of 8.64%. Contineum Therapeutics has a consensus price target of $21.40, suggesting a potential upside of 124.08%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Pacira BioSciences has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$726.41M2.01$7.03M$0.35104.24
Contineum TherapeuticsN/AN/A-$59.98M-$1.77N/A

Pacira BioSciences has a net margin of 5.08% compared to Contineum Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 10.82% beat Contineum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences5.08% 10.82% 6.01%
Contineum Therapeutics N/A -25.48%-24.28%

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Pacira BioSciences had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Pacira BioSciences and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.96 beat Pacira BioSciences' score of 0.46 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Pacira BioSciences beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTNM vs. The Competition

MetricContineum TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$374.99M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-5.4029.4134.1729.85
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book1.535.114.373.66
Net Income-$59.98M$2.88B$3.52B$392.27M
7 Day Performance-9.56%-4.11%-5.47%-4.72%
1 Month Performance34.89%-5.09%-4.58%-7.14%
1 Year Performance-14.35%-7.45%-1.79%-7.51%

Contineum Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTNM
Contineum Therapeutics
1.8249 of 5 stars
$9.55
-1.2%
$21.40
+124.1%
-9.3%$374.99MN/AN/A51
RAPP
Rapport Therapeutics
4.0167 of 5 stars
$26.53
+2.2%
$64.50
+143.1%
+1.8%$1.57BN/AN/A84
GPCR
Structure Therapeutics
2.9622 of 5 stars
$21.37
-1.6%
$110.91
+418.9%
-49.6%$1.48BN/AN/A281
LBRX
LB Pharmaceuticals
2.1684 of 5 stars
$44.78
-0.4%
$57.40
+28.2%
+188.3%$1.46BN/AN/A27
OCUL
Ocular Therapeutix
2.5003 of 5 stars
$6.62
+0.2%
$23.83
+259.8%
-46.8%$1.45B$50.38MN/A325

Related Companies and Tools


This page (NASDAQ:CTNM) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners